Pharmaceutical companies are accelerating capital allocations toward specialized contract development and manufacturing organizations (CDMOs) to eliminate persistent supply constraints for peptide-based metabolic therapeutics.
Fill-Finish Capacity Constraints
Sterile filling facilities represent the primary structural bottleneck in the distribution chain. Industry capital expenditure targeting parenteral assembly lines is expected to grow 28% over the next 24 months to normalize inventory backlogs.